Antibiotics are a specific class of antimicrobial agents that are designed to target and combat bacterial infections. These drugs are widely used in the treatment and prevention of bacterial infections due to their high effectiveness against bacteria. Antibiotics work by interfering with the growth and replication of bacteria, either by inhibiting their cell wall synthesis, protein production, or DNA replication. Their targeted action makes them a powerful tool in combating bacterial diseases and promoting overall health.
According to Data Bridge Market Research, the Antibiotic Production Market accounted for USD 40.70 billion in 2021 and is expected to reach USD 61.29 billion by 2029. The market is expected to grow with a CAGR of 5.25% in the forecast period of 2022 to 2029.
“Growing number of patients”
The antibiotic production market is experiencing growth due to an increasing number of patients suffering from infectious diseases. With the rise in infectious diseases globally, there is a greater need for effective antibiotics to combat bacterial infections. This has fuelled the demand for antibiotic production, as pharmaceutical companies and researchers focus on developing new and improved antibiotics to address emerging infectious threats. The growing patient population and the urgent need for effective treatment options are driving the growth of the antibiotic production market.
What restraints the growth of the antibiotic production market?
“Increased drug endorsement costs”
The antibiotic production market is facing constraints due to the increased costs associated with drug endorsements. The process of developing and bringing antibiotics to market involves significant investments in research, clinical trials, regulatory approvals, and marketing activities. These endorsement costs can be substantial and pose challenges for pharmaceutical companies, hindering the production and availability of antibiotics. As a result, the antibiotic production market may face limitations in growth and the ability to meet the increasing demand for effective antimicrobial treatments.
Segmentation: Antibiotic Production Market
The antibiotic production market is segmented on the basis of drug origin, spectrum of activity, route of administration, and class.
- On the basis of drug origin, the antibiotic production market has been segmented into natural, semisynthetic, and synthetic.
- On the basis spectrum of activity, the antibiotic production market has been segmented into broad-spectrum antibiotic and narrow-spectrum antibiotic.
- On the basis of route of administration, the antibiotic production market has been segmented into oral, intravenous, and others.
- 根據類別，抗生素生產市場細分為β-內醯胺和β-內醯胺酶、喹諾酮類、大環內酯類和其他。
區域洞察：北美主導抗生素生產市場
由於老年人口的不斷增加和創新醫療技術的採用，北美在抗生素生產市場佔據主導地位。隨著老年人口的增加，與年齡相關的健康狀況和感染的盛行率也隨之上升，從而推動了對抗生素的需求。
預計亞太地區在 2022 年至 2029 年預測期內的成長率最高。抗生素生產市場正在經歷成長，因為成熟的市場參與者專注於擴大在該地區的業務，因為該地區在數量和收入方面具有豐厚的市場機會。
要了解有關該研究的更多信息，請訪問：https://www.databridgemarketresearch.com/reports/global-antibiotic-production-market
近期發展
- 2020 年 10 月，輝瑞宣布收購專注於研發用於治療抗藥性革蘭氏陰性感染的下一代口服抗生素的 Arixa Pharmaceuticals Inc.。
抗生素生產市場的主要參與者包括：
- 雅培（美國）
- F.Hoffmann-La Roche有限公司（瑞士）
- 艾爾建（愛爾蘭）
- 安進公司（美國）
- 葛蘭素史克公司（英國）
- 默克夏普和多姆公司（美國）
- 諾華公司（瑞士）
- 輝瑞公司（美國）
- 強生私人有限公司（美國）
- Mylan N.V.（美國）
- 梯瓦製藥工業股份有限公司（美國）
- 賽諾菲（法國）
以上是報告中涉及的關鍵參與者，要了解更多抗生素生產市場公司聯絡方式的詳盡列表，請訪問 https://www.databridgemarketresearch.com/contact
研究方法：全球抗生素生產市場
資料收集和基準年分析是使用具有大樣本量的資料收集模組完成的。使用市場統計和相干模型來分析和估計市場數據。此外，市場佔有率分析和關鍵趨勢分析是市場報告中的主要成功因素。 DBMR 研究團隊使用的關鍵研究方法是資料三角測量，其中涉及資料探勘、資料變數對市場的影響分析以及初步（產業專家）驗證。除此之外，資料模型還包括供應商定位網格、市場時間軸分析、市場概覽和指南、公司定位網格、公司市場份額分析、測量標準、全球與區域以及供應商份額分析。如有進一步疑問，請要求分析師致電。
